The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).
 
Maria Amaya
No Relationships to Disclose
 
Christine McMahon
Consulting or Advisory Role - Abbvie (I); Arcellx; Kura Oncology; TG Therapeutics (I)
Research Funding - Syndax (Inst); Syros Pharmaceuticals (Inst)
 
Jonathan Aaron Gutman
No Relationships to Disclose
 
Brett Stevens
No Relationships to Disclose
 
Connor Sohalski
No Relationships to Disclose
 
Jennifer Tobin
Honoraria - JADPRO; NCCN
 
Clayton Smith
Research Funding - Argenx; Kura Oncology; Syros Pharmaceuticals
Patents, Royalties, Other Intellectual Property - University of Colorado
 
Craig Jordan
No Relationships to Disclose
 
Daniel Aaron Pollyea
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; Aptevo Therapeutics; Arcellx; AstraZeneca; BeiGene; BerGenBio; Bristol-Myers Squibb; Daiichi Sankyo/Arqule; Genentech; Gilead Sciences; HiberCell; Immunogen; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Karyopharm Therapeutics; Kura Oncology; Link Pharma; Magenta Therapeutics; Medivir; Novartis; Qihan Biotech; Rigel; Ryvu Therapeutics; Sumitomo Dainippon Pharma Oncology; Syndax; Syros Pharmaceuticals; Zentalis
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Karyopharm Therapeutics (Inst); Teva (Inst)